Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848207 | 1.00 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848209 | 1.00 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9325738 | 0.87 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12662601 | 0.87 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1844443 | 0.87 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5520518 | 0.86 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20478894 | 0.86 | CA1 (0.52) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24542993 | 0.85 | TAS1R3 (0.43) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29724351 | 0.85 | TAS1R3 (0.43) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6244196 | 0.84 | TAS1R3 (0.46) | CA1CA2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | CA1 500/4885CA2 636/4885TAS1R3 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.